EFCG says EU directive does not address API quality issues, calls for mandatory inspection of API manufacturing sites

The European Fine Chemicals Group (EFCG; Brussels), an industry association that is part of Cefic, says that the European Union's new Falsified Medicines Directive, which is designed to minimize counterfeit medicines entering the EU market, does not adequately address quality issues relating to active pharmaceutical ingredients (API) and does little to improve upon the present directive pertaining to patient safety. EFCG represents more than 40 fine chemical manufacturers and trade bodies in the European Union that are involved in the global pharmaceutical supply...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers